JP2025509262A5 - - Google Patents
Info
- Publication number
- JP2025509262A5 JP2025509262A5 JP2024553307A JP2024553307A JP2025509262A5 JP 2025509262 A5 JP2025509262 A5 JP 2025509262A5 JP 2024553307 A JP2024553307 A JP 2024553307A JP 2024553307 A JP2024553307 A JP 2024553307A JP 2025509262 A5 JP2025509262 A5 JP 2025509262A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- seq
- expression vector
- shrna
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317155P | 2022-03-07 | 2022-03-07 | |
| US63/317,155 | 2022-03-07 | ||
| PCT/US2023/014680 WO2023172535A2 (en) | 2022-03-07 | 2023-03-07 | shRNA TARGETING SNORD115 LOCATIONS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN SYNDROME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509262A JP2025509262A (ja) | 2025-04-11 |
| JP2025509262A5 true JP2025509262A5 (enExample) | 2026-03-16 |
Family
ID=87935834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553307A Pending JP2025509262A (ja) | 2022-03-07 | 2023-03-07 | アンジェルマン症候群における父方由来ＵＢＥ３Ａ遺伝子発現を回復させるためのＳＮＯＲＤ１１５の位置を標的とするｓｈＲＮＡ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230332150A1 (enExample) |
| EP (1) | EP4473116A2 (enExample) |
| JP (1) | JP2025509262A (enExample) |
| KR (1) | KR20240155345A (enExample) |
| CN (1) | CN119384504A (enExample) |
| AU (1) | AU2023231550A1 (enExample) |
| CA (1) | CA3259398A1 (enExample) |
| IL (1) | IL315359A (enExample) |
| MX (1) | MX2024010820A (enExample) |
| WO (1) | WO2023172535A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025101533A1 (en) * | 2023-11-09 | 2025-05-15 | Encoded Therapeutics, Inc. | Methods and compositions for increasing expression of ube3a |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013098381A1 (en) * | 2011-12-28 | 2013-07-04 | Universite Pierre Et Marie Curie (Paris 6) | Rna interference to activate stem cells |
| KR102723989B1 (ko) * | 2017-12-01 | 2024-11-01 | 더 텍사스 에이 & 엠 유니버시티 시스템 | 엔젤만 증후군 안티센스 치료 |
| WO2020061528A1 (en) * | 2018-09-21 | 2020-03-26 | University Of Connecticut | Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome |
| CA3133294A1 (en) * | 2019-03-15 | 2020-09-24 | Mir Scientific, Llc | Methods for predicting prostate cancer and uses thereof |
-
2023
- 2023-03-07 CN CN202380026096.6A patent/CN119384504A/zh active Pending
- 2023-03-07 CA CA3259398A patent/CA3259398A1/en active Pending
- 2023-03-07 KR KR1020247033390A patent/KR20240155345A/ko active Pending
- 2023-03-07 EP EP23767380.1A patent/EP4473116A2/en active Pending
- 2023-03-07 JP JP2024553307A patent/JP2025509262A/ja active Pending
- 2023-03-07 US US18/179,716 patent/US20230332150A1/en active Pending
- 2023-03-07 IL IL315359A patent/IL315359A/en unknown
- 2023-03-07 WO PCT/US2023/014680 patent/WO2023172535A2/en not_active Ceased
- 2023-03-07 AU AU2023231550A patent/AU2023231550A1/en active Pending
-
2024
- 2024-09-04 MX MX2024010820A patent/MX2024010820A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230119344A1 (en) | Rnai induced huntingtin gene suppression | |
| JP2022518504A5 (enExample) | ||
| IL278213B1 (en) | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) | |
| JP2022513456A5 (enExample) | ||
| JP2022046792A (ja) | 組織特異的発現のための改変ｕ６プロモーターシステム | |
| CN102227500A (zh) | 胆色素原脱氨酶基因治疗 | |
| JP2020054367A (ja) | 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用 | |
| JP2022505381A5 (enExample) | ||
| CA3165624A1 (en) | Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement | |
| US20220380798A1 (en) | AAV Expression Cassette and AAV Vectors Comprising the Same | |
| JP2024508696A5 (enExample) | ||
| WO2024006741A1 (en) | Aav capsid variants and uses thereof | |
| EP4069263A1 (en) | Transgene cassettes designed to express a human mecp2 gene | |
| JP2023500793A5 (enExample) | ||
| JP2023553005A (ja) | 末梢ミエリンタンパク質２２の発現の阻害のための生成物及び方法 | |
| JP2021534794A5 (enExample) | ||
| EP4627093A1 (en) | Adeno-associated viral vectors for proper packaging of repetitive elements | |
| JP2025509262A5 (enExample) | ||
| JP2025512709A5 (enExample) | ||
| JP2022554141A5 (enExample) | ||
| JP2025534169A (ja) | ｓｎＲＮＡ核酸分子およびその使用 | |
| CN119654414A (zh) | 病毒载体 | |
| JP2022523320A5 (enExample) | ||
| EP4077643A1 (en) | Parvoviral vectors and methods of making and use thereof | |
| US20250230437A1 (en) | Novel systems for nucleic acid regulation |